Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-104-6 | CAS number: 103-36-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
The test substance is not genotoxic under the conditions tested.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- Restriction: No strain included that could detect certain oxidising or cross-linking agents (e.g. TA 102); no information on positive control substances
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- The method of Ames, McCann & Yamasaki (1975) was followed.
- Deviations:
- yes
- Remarks:
- Deviation from OECD TG 471: No strain included that could detect certain oxidising or cross-linking agents (e.g. TA 102)
- GLP compliance:
- no
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- his operon
- Species / strain / cell type:
- S. typhimurium, other: TA92
- Details on mammalian cell type (if applicable):
- The test strain was originally provided by Dr B. N. Ames, University of California, Berkeley, USA.
- Species / strain / cell type:
- S. typhimurium, other: TA94
- Details on mammalian cell type (if applicable):
- The test strain was originally provided by Dr B. N. Ames, University of California, Berkeley, USA.
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Details on mammalian cell type (if applicable):
- The test strains were originally provided by Dr B. N. Ames, University of California, Berkeley, USA.
- Metabolic activation:
- with and without
- Metabolic activation system:
- liver microsome fraction (S-9) prepared from the liver of Fischer rats (Charles River Japan Co.)
- Test concentrations with justification for top dose:
- Six concentrations were tested (max. 5.0 mg/plate) to determine the maximum dose.
- Vehicle / solvent:
- dimethylsulphoxide (DMSO)
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: preincubation with the test sample and with or without the S-9 mix
DURATION Preincubation: 20 min at 37°C
NUMBER OF REPLICATIONS: 2 for each concentration
OTHER: If no reasonable dose response was detected, additional experiments using different doses or induced mutation frequency assays were performed. - Evaluation criteria:
- The number of revertant (his+) colonies was scored after incubation at 37°C for 2 days.
The result was considered positive if the number of colonies found was twice the number in the control (exposed to the appropriate solvent or untreated). - Species / strain:
- S. typhimurium, other: TA94
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Species / strain:
- S. typhimurium, other: TA92
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Additional information on results:
- The maximum dose was 5.0 mg/plate, which represents the highest non-cytotoxic dose used in the experiment.
- Conclusions:
- The test item was found not to be genotoxic in an Ames test using the S. typhimurium strains TA92, TA1535, TA100, TA1537, TA94 and TA98.
- Executive summary:
In the current study no OECD guideline was followed and the study was not according to GLP, however, the method of Ames, McCann & Yamasaki (1975) was followed which is similar to the OECD Guideline 471.
The assay included the S. typhimurium strains TA92, TA1535, TA100, TA1537, TA94 and TA98 and the genotoxicity of the test item was investigated with and without metabolic activation, which was the liver microsome fraction (S-9) from Fischer rats.
The test item was found to be negative for all S. typhimurium strains, which indicates that no significant increase in the number of revertant colonies were detected at a maximum dose of 5.0 mg/plate, at which no cytotoxic effects were observed.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- V79 (Chinese hamster) cells at the HPRT locus
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 30.06.-20.08.2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- 1997
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- 2008
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Hess. Ministerium fuer Umwelt, Klimaschutz, Landwirtschaft und Verbraucherschutz, Wiesbaden
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- HPRT (hypoxanthine-guanine phosphoribosyl transferase)
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Details on mammalian cell type (if applicable):
- - Source: Laboratory for Mutagenicity Testing; Technical University, Germany
- Medium: MEM (minimal essential medium) supplemented with Hank’s salts, 10% Fetal Bovine Serum (except during 4 hour treatment), neomycin (5 μg/mL) and amphotericin B (1%). For the selection of mutant cells the complete medium was supplemented with 11 μg/mL 6-thioguanine.
- Culture conditions: 37°C in a 1.5% carbon dioxide atmosphere (98.5% air). - Metabolic activation:
- with and without
- Metabolic activation system:
- co-factor supplemented post-mitochondrial fraction (S9 mix), prepared from the livers of rats treated with Phenobarbital / ß-naphthoflavone
- Test concentrations with justification for top dose:
- The test concentrations were selected based on the pre- experiment.
Experiment I:
4 hours: 6.9; 13.8; 27.5; 55, 110 and 220 µg/mL
Experiment II:
24 hours: 13.8; 27.5; 55, 110 and 165 µg/mL
4 hours: 6.9; 13.8; 27.5; 55, 110 and 220 µg/mL - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: The solvent was chosen due to its solubility properties and its relative non-toxicity to the cell cultures. - Negative solvent / vehicle controls:
- yes
- Positive controls:
- yes
- Positive control substance:
- 7,12-dimethylbenzanthracene
- ethylmethanesulphonate
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium in flask
DURATION: Expression time (cells in growth medium): 7 days
STAIN (for cytogenetic assays): 10% methylene blue in 0.01% KOH solution
NUMBER OF REPLICATIONS: 2
NUMBER OF CELLS EVALUATED: stained colonies with more than 50 cells were counted
POSITIVE CONTROLS:
- 4h treatment, without S9 mix: EMS, 150 µg/mL
- 4h treatment, with S9 mix: DMBA, 1.1 µg/mL
- 24h treatment, without S9 mix: EMS, 150 µg/mL
- 24h treatment, with S9 mix: DMBA, 1.1 µg/mL - Evaluation criteria:
- The gene mutation assay is considered acceptable if:
a) the amount of mutant colonies per 10e6 cells found in the solvent controls fall within the laboratory historical control data range.
b) the positive control substances produce a significant increase in mutant colony frequencies and remain within the historical control range of positive controls.
c) the cloning efficiency II (absolute value) of the solvent controls exceeds 50%. - Statistics:
- A linear regression (least squares) was performed to assess a possible dose dependent increase of mutant frequencies. The numbers of mutant colonies generated with the test item were compared to the solvent control groups. A trend is judged as significant whenever the p-value (probability value) is below 0.05. However, both, biological and statistical significance was considered together.
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Phase separation was noted in experiment I at 110.0 μg/mL and above with and without metabolic activation. In the second experiment phase separation occurred at 220 μg/mL with metabolic activation.
In both experiments of this study (with and without S9 mix) the range of the solvent controls was from 12.9 up to 28.7 mutants per 10e6 cells; the range of the groups treated with the test item was from 10.4 up to 51.0 mutants per 10e6 cells.
EMS (150 μg/mL) and DMBA (1.1 μg/mL) were used as positive controls and showed a distinct increase in induced mutant colonies. - Conclusions:
- Under the experimental conditions here the test item did not induce gene mutations at the HPRT locus in V79 cells, and thus, is considered to be non-mutagenic in this HPRT assay.
- Executive summary:
In the current study the potential of the test item to induce gene mutations was assessed at the HPRT locus using V79 cells of the Chinese hamster. The OECD guideline 476 was followed and the study was GLP-compliant.
The V79 cells are exposed to the test item both with and without exogenous metabolic activation. At a defined time interval after treatment the descendants of the treated original population are monitored for the loss of functional HPRT enzyme.
The assay was performed in two independent experiments. The cells were exposed to the test item for 4 hours in the first experiment with and without metabolic activation. The second experiment was performed with a treatment time of 4 hours with and 24 hours without metabolic activation.
The concentration range of the main experiments was limited by cytotoxicity and solubility of the test item.
The tested concentrations were:
Experiment I:
4 hours: 6.9; 13.8; 27.5; 55, 110 and 220 µg/mL
Experiment II:
24 hours: 13.8; 27.5; 55, 110 and 165 µg/mL
4 hours: 6.9; 13.8; 27.5; 55, 110 and 220 µg/mL
No substantial and reproducible dose dependent increase of the mutation frequency was observed in both main experiments.
Appropriate reference mutagens, used as positive controls, induced a distinct increase in mutant colonies and thus, showed the sensitivity of the test system and the activity of the metabolic activation system.
It can be stated that under the experimental conditions reported the test item did not induce gene mutations at the HPRT locus in V79 cells. Therefore, the test item is considered to be non-mutagenic in this HPRT assay.
- Endpoint:
- in vitro cytogenicity / micronucleus study
- Remarks:
- In vitro micronucleus test in human lymphocytes
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 08.07 - 06.08.2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 487 (In vitro Mammalian Cell Micronucleus Test)
- Version / remarks:
- September 2014
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Hess. Ministerium fuer Umwelt, Klimaschutz, Landwirtschaft und Verbraucherschutz, Wiesbaden
- Type of assay:
- in vitro mammalian cell micronucleus test
- Target gene:
- Not applicable
- Species / strain / cell type:
- lymphocytes: human lymphocytes from healthy non-smoking donors not receiving medication
- Details on mammalian cell type (if applicable):
- Type and identity of media: Dulbecco's Modified Eagles Medium/Ham's F12 (DMEM/F12, mixture1:1) supplemented with 200mM GlutaMAXTM, penicillin/streptomycin (100 U/mL/100 μg/mL), the mitogen PHA (3 μg/mL), 10 % FBS (fetal bovine serum), 10 mM HEPES and anticoagulant heparin (125 U.S.P.-U/mL).
- Metabolic activation:
- with and without
- Metabolic activation system:
- co-factor supplemented post-mitochondrial fraction (S9 mix), prepared from the livers of rats treated with Phenobarbital / ß-naphthoflavone
- Test concentrations with justification for top dose:
- 11.4 to 1760.0 μg/mL
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: The solvent was chosen due to its solubility properties and its relative non-toxicity to the cell cultures. - Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- mitomycin C
- other: demecolcin
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium in culture flasks
DURATION: See 'Any other information'
SPINDLE INHIBITOR (cytogenetic assays): cytochalasin B
STAIN (for cytogenetic assays): Giemsa
NUMBER OF REPLICATIONS: 2
NUMBER OF CELLS EVALUATED: 1000 binucleated cells were evaluated for cytogenetic damage.
DETERMINATION OF CYTOTOXICITY
- Method: CBPI, cytotoxicity is expressed as % cytostasis
POSITIVE CONTROLS:
- Exposure period 4h without S9 mix: MMC, 1.0 µg/mL
- Exposure period 20h without S9 mix: Demecolcin, 125.0 ng/mL
- Exposure period 4h with S9 mix: CPA, 17.5 µg/mL - Evaluation criteria:
- The criteria for the evaluation of micronuclei are described in the publication of Countryman and Heddle (1976).
- Statistics:
- Statistical significance was confirmed by using the Chi-squared test (α < 0.05) using the validated R Script CHI2.Rnw for those values that indicated an increase in the number of cells with micronuclei compared to the concurrent solvent control.
- Species / strain:
- lymphocytes: human
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- No relevant influence on osmolarity or pH was observed.
Phase separation was observed at the end of treatment at 187.7 μg/mL and above in Experiment I in the absence and presence of S9 mix and at 328.0 μg/mL and above in Experiment II in the absence of S9 mix.
In Experiment I in the absence and presence of S9 mix, no cytotoxicity was observed up to the highest evaluated concentration, which showed phase separation. In Experiment II in the absence of S9 mix and continuous treatment the concentrations showing clear cytotoxic effects were not evaluable for cytogenetic damage.
In both independent experiments, neither a statistically significant nor a biologically relevant increase in the number of micronucleated cells was observed after treatment with the test item.
In both experiments, either Demecolcin (125.0 ng/mL), MMC (1.0 μg/mL) or CPA (17.5 μg/mL) were used as positive controls and showed distinct increases in cells with micronuclei. - Conclusions:
- The test item did not induce micronuclei as determined by the in vitro micronucleus test in human lymphocytes and is therefore considered to be not mutagenic.
- Executive summary:
In the current study the potential of the test item to induce chromosomal aberrations was investigated in an in vitro micronucleus assay. The OECD guideline 487 was followed and the study was GLP-compliant.
The induction of cytogenetic damage in human lymphocytes (from healthy non-smoking donors) was assessed in two independent experiments.
Cytochalasin B was used as cytokinesis blocker to ensure that only binucleate cells were evaluated for micronuclei.
Treatments started after a 48 hour stimulation period with phytohemeagglutinine (PHA) when cells were actively proliferating and the cells were prepared at approximately 2 – 2.5 fold of the normal cell cycle time.
For validation of the test, control mutagens were tested in parallel to the test item.
In each experimental group two parallel cultures were analysed. Per culture 1000 binucleated cells were evaluated for cytogenetic damage. The highest applied concentration in this study (1760.0 μg/mL of the test item, approx. 10 mM) was chosen with regard to the molecular weight of the test item and with respect to the current OECD Guideline 487.
Dose selection of the cytogenetic experiment was performed considering the toxicity data and the occurrence of test item phase separation in accordance with OECD Guideline 487.
In Experiment I in the absence and presence of S9 mix, no cytotoxicity was observed up to the highest evaluated concentration, which showed phase separation. In Experiment II in the absence of S9 mix and continuous treatment, the concentrations showing clear cytotoxic effects were not evaluable for cytogenetic damage.
In both independent experiments, neither a statistically significant nor a biologically relevant increase in the number of micronucleated cells was observed after treatment with the test item.
Appropriate mutagens were used as positive controls. They induced statistically significant increases in cells with micronuclei.
Therefore, under the experimental conditions reported here, the test item did not induce micronuclei as determined by the in vitro micronucleus test in human lymphocytes and is considered to be not mutagenic (not clastogenic and not aneugenic).
Referenceopen allclose all
relative | relative | relative | mutant | relative | relative | relative | mutant | ||||||
conc. | P/ | S9 | cloning | cell | cloning | colonies/ | induction | cloning | cell | cloning | colonies/ | induction | |
μg/mL | PS | mix | efficiency1 | density | efficiency II | 106 cells | factor | efficiency1 | density | efficiency II | 106 cells | factor | |
% | % | % | % | % | % | ||||||||
Column | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 |
Experiment I / 4 h treatment | culture I | culture II | |||||||||||
Solvent control | - | 100 | 100 | 100 | 22.4 | 1 | 100 | 100 | 100 | 15.5 | 1 | ||
Positive control (EMS) | 150 | - | 81 | 121.9 | 74.6 | 231.2 | 10.3 | 100.9 | 116.7 | 83.1 | 217.1 | 14 | |
Test item | 6.9 | - | 101.9 | 118.4 | 76.5 | 25.9 | 1.2 | 76.6 | 101.5 | 93.8 | 12.1 | 0.8 | |
Test item | 13.8 | - | 109.4 | 86.8 | 90.2 | 18.6 | 0.8 | 81.7 | 95.9 | 100.2 | 15.8 | 1 | |
Test item | 27.5 | - | 85.4 | 91.3 | 90.3 | 27.6 | 1.2 | 81.7 | 112 | 96.5 | 26.8 | 1.7 | |
Test item | 55 | - | 91.3 | 127.3 | 72.9 | 49.5 | 2.2 | 85.6 | 130 | 103.2 | 37.9 | 2.5 | |
Test item | 110 | PS | - | 56.7 | 32.3 | 87.2 | 24.2 | 1.1 | 58.8 | 32.6 | 112.6 | 36.5 | 2.4 |
Test item | 220 | PS | - | 0 | culture was not continued# | culture was not continued# | |||||||
Solvent control | + | 100 | 100 | 100 | 12.9 | 1 | 100 | 100 | 100 | 20.1 | 1 | ||
Positive control (DMBA) | 2.2 | + | 79.9 | 109 | 87.7 | 133.2 | 10.4 | 78.8 | 92.3 | 75.7 | 267.6 | 13.3 | |
Test item | 6.9 | + | 100.4 | culture was not continued# | 94.6 | culture was not continued# | |||||||
Test item | 13.8 | + | 99.1 | 99.6 | 88 | 23.4 | 1.8 | 96.7 | 107.2 | 94.7 | 21.9 | 1.1 | |
Test item | 27.5 | + | 96.9 | 83.6 | 86.6 | 13.2 | 1 | 97.4 | 120 | 98.3 | 13 | 0.6 | |
Test item | 55 | + | 106.6 | 106.6 | 82.9 | 15.8 | 1.2 | 94.8 | 126.3 | 99.8 | 44.4 | 2.2 | |
Test item | 110 | PS | + | 98.4 | 118.1 | 82.9 | 28.8 | 2.2 | 95.7 | 123 | 101.6 | 16.5 | 0.8 |
Test item | 220 | PS | + | 101.2 | 100.6 | 83.2 | 19.8 | 1.5 | 97.9 | 111.9 | 96.1 | 42.1 | 2.1 |
Experiment II / 24 h treatment | culture I | culture II | |||||||||||
Solvent control | - | 100 | 100 | 100 | 28.7 | 1 | 100 | 100 | 100 | 19.4 | 1 | ||
Positive control (EMS) | 150 | - | 97.1 | 81.1 | 78.2 | 135.4 | 4.7 | 106.5 | 86.5 | 93.4 | 115.9 | 6 | |
Test item | 13.8 | - | 97.5 | 72.9 | 87.6 | 12.2 | 0.4 | 105.6 | 90.1 | 96.3 | 14.9 | 0.8 | |
Test item | 27.5 | - | 99.4 | 90.3 | 82.5 | 21.8 | 0.8 | 100.7 | 91.7 | 98.9 | 11.3 | 0.6 | |
Test item | 55 | - | 100 | 104.9 | 94.3 | 19.2 | 0.7 | 101.5 | 103.2 | 88.9 | 35.3 | 1.8 | |
Test item | 110 | - | 97 | 129.9 | 91.7 | 22.6 | 0.8 | 91.4 | 101.6 | 89.9 | 27 | 1.4 | |
Test item | 165 | - | 47.9 | 9.6 | 78.8 | 14.8 | 0.5 | 51.7 | 9.4 | 78.4 | 51 | 2.6 | |
Test item | 220 | PS | - | 0 | 1.5 | culture was not continued# | 0 | 0 | culture was not continued# | ||||
Experiment II / 4 h treatment | culture I | culture II | |||||||||||
Solvent control | + | 100 | 100 | 100 | 26.7 | 1 | 100 | 100 | 100 | 15.3 | 1 | ||
Positive control (DMBA) | 2.2 | + | 99.6 | 98.9 | 91.3 | 177.5 | 6.4 | 92.7 | 98.7 | 80.9 | 194.8 | 12.7 | |
Test item | 6.9 | + | 92.2 | culture was not continued# | 91.2 | culture was not continued# | |||||||
Test item | 13.8 | + | 99.4 | 101.1 | 98 | 20.1 | 0.7 | 88.3 | 89.1 | 87 | 20.6 | 1.3 | |
Test item | 27.5 | + | 89.2 | 100.5 | 97.6 | 23.5 | 0.9 | 91.8 | 103.4 | 90.3 | 18.1 | 1.2 | |
Test item | 55 | + | 94.2 | 91.9 | 97.3 | 13.6 | 0.5 | 88.6 | 122 | 89.1 | 10.4 | 0.7 | |
Test item | 110 | + | 82.1 | 105.7 | 96.3 | 22.8 | 0.8 | 82.3 | 106 | 85.7 | 12.3 | 0.8 | |
Test item | 220 | PS | + | 75.5 | 65.5 | 90.7 | 17.3 | 0.6 | 75.9 | 92.9 | 88.8 | 15 | 1 |
PS = Phase separation
# culture was not continued due to exceedingly severe cytotoxic effects
## culture was not continued since a minimum of only four analysable concentrations is required
Experiment I
Cytotoxicity indicated as cytokinesis-block proliferation index and cytostasis; exposure period 4 hrs without S9 mix.
Treatment group | Conc. Per mL | S9 mix | Exposure/preparation | Cell proliferation culture 1* | Proliferation Index CBPI | Cell proliferation culture 2* | Proliferation Index CBPI | CBPI mean | Cytostasis [%] | ||||
c1 | c2 | c4-c8 | c1 | c2 | c4-c8 | ||||||||
Solv. control# | 0.50% | - | 4 / 40 hrs | 84 | 374 | 42 | 1.92 | 100 | 367 | 33 | 1.87 | 1.89 | |
Pos. control## | 1.0 μg | - | 4 / 40 hrs | 331 | 164 | 5 | 1.35 | 338 | 158 | 4 | 1.33 | 1.34 | 61.8 |
Test item | 61.3 μg | - | 4 / 40 hrs | 76 | 387 | 37 | 1.92 | 99 | 361 | 40 | 1.88 | 1.9 | n.c. |
″ | 107.2 μg | - | 4 / 40 hrs | 100 | 367 | 33 | 1.87 | 75 | 378 | 47 | 1.94 | 1.91 | n.c. |
″ | 187.7 μg | - | 4 / 40 hrs | 205 | 288 | 7 | 1.6 | 150 | 342 | 8 | 1.72 | 1.66 | 25.9 |
* c1: mononucleate cells; c2: binucleate cells; c4-c8: multinucleate cells
# DMSO
## MMC
n.c. Not calculated as the CBPI is equal or higher than the solvent control value
Cytotoxicity indicated as cytokinesis-block proliferation index and cytostasis; exposure period 4 hrs with S9 mix
Treatment group | Conc. Per mL | S9 mix | Exposure/preparation | Cell proliferation culture 1* | Proliferation Index CBPI | Cell proliferation culture 2* | Proliferation Index CBPI | CBPI mean | Cytostasis [%] | ||||
c1 | c2 | c4-c8 | c1 | c2 | c4-c8 | ||||||||
Solv. control# | 0.50% | + | 4 / 40 hrs | 80 | 381 | 39 | 1.92 | 126 | 348 | 26 | 1.8 | 1.86 | |
Pos. control## | 17.5 μg | + | 4 / 40 hrs | 277 | 215 | 8 | 1.46 | 256 | 235 | 9 | 1.51 | 1.48 | 43.7 |
Test item | 61.3 μg | + | 4 / 40 hrs | 96 | 368 | 36 | 1.88 | 100 | 365 | 35 | 1.87 | 1.88 | n.c. |
″ | 107.2 μg | + | 4 / 40 hrs | 131 | 338 | 31 | 1.8 | 158 | 314 | 28 | 1.74 | 1.77 | 10.4 |
″ | 187.7 μg | + | 4 / 40 hrs | 129 | 342 | 29 | 1.8 | 132 | 339 | 29 | 1.79 | 1.8 | 7.2 |
* c1: mononucleate cells; c2: binucleate cells; c4-c8: multinucleate cells
# DMSO
## MMC
n.c. Not calculated as the CBPI is equal or higher than the solvent control value
Number of micronucleated cells; exposure period 4 hrs without S9 mix
Treatment group | Conc. per mL | S9 mix | Exposure/preparation | Binucleate cells with n micronuclei culture 1 | sum culture 1 | Micronucleated cells Binucleate cells with n micronuclei culture 2 | sum culture 2 | sum in 2000 binucleate cells | [%] | ||||
1 | 2 | >2 | 1 | 2 | >2 | ||||||||
Solv. control# | 0.50% | - | 4 / 40 hrs | 4 | 0 | 0 | 4 | 5 | 0 | 1 | 6 | 10 | 0.5 |
Pos. control## | 1.0 μg | - | 4 / 40 hrs | 153 | 19 | 2 | 174 | 179 | 11 | 5 | 195 | 369 | 18.45 |
Test item | 61.3 μg | - | 4 / 40 hrs | 4 | 1 | 0 | 5 | 9 | 0 | 0 | 9 | 14 | 0.7 |
″ | 107.2 μg | - | 4 / 40 hrs | 5 | 0 | 0 | 5 | 7 | 0 | 1 | 8 | 13 | 0.65 |
″ | 187.7 μg | - | 4 / 40 hrs | 5 | 0 | 0 | 5 | 6 | 1 | 0 | 7 | 12 | 0.6 |
# DMSO
## MMC
Number of micronucleated cells; exposure period 4 hrs with S9 mix
Treatment group | Conc. per mL | S9 mix | Exposure/preparation | Binucleate cells with n micronuclei culture 1 | sum culture 1 | Micronucleated cells Binucleate cells with n micronuclei culture 2 | sum culture 2 | sum in 2000 binucleate cells | [%] | ||||
1 | 2 | >2 | 1 | 2 | >2 | ||||||||
Solv. control# | 0.50% | + | 4 / 40 hrs | 5 | 0 | 0 | 5 | 4 | 1 | 0 | 5 | 10 | 0.5 |
Pos. control## | 17.5 μg | + | 4 / 40 hrs | 57 | 4 | 0 | 61 | 60 | 1 | 0 | 61 | 122 | 6.1 |
Test item | 61.3 μg | + | 4 / 40 hrs | 7 | 0 | 0 | 7 | 5 | 0 | 0 | 5 | 12 | 0.6 |
″ | 107.2 μg | + | 4 / 40 hrs | 4 | 1 | 0 | 5 | 3 | 0 | 0 | 3 | 8 | 0.4 |
″ | 187.7 μg | + | 4 / 40 hrs | 4 | 0 | 0 | 4 | 7 | 0 | 0 | 7 | 11 | 0.55 |
# DMSO
## MMC
Experiment II
Cytotoxicity indicated as cytokinesis-block proliferation index and cytostasis; exposure period 20 hrs without S9 mix
Treatment group | Conc. Per mL | S9 mix | Exposure/preparation | Cell proliferation culture 1* | Proliferation Index CBPI | Cell proliferation culture 2* | Proliferation Index CBPI | CBPI mean | Cytostasis [%] | ||||
c1 | c2 | c4-c8 | c1 | c2 | c4-c8 | ||||||||
Solv. control# | 0.50% | - | 20 / 40 hrs | 40 | 400 | 60 | 2.04 | 69 | 381 | 50 | 1.96 | 2 | |
Pos. control## | 125.0 ng | - | 20 / 40 hrs | 123 | 367 | 10 | 1.77 | 124 | 358 | 18 | 1.79 | 1.78 | 22 |
Test item | 35.0 μg | - | 20 / 40 hrs | 29 | 421 | 50 | 2.04 | 47 | 417 | 36 | 1.98 | 2.01 | n.c. |
″ | 61.3 μg | - | 20 / 40 hrs | 45 | 417 | 38 | 1.99 | 65 | 404 | 31 | 1.93 | 1.96 | 4.2 |
″ | 107.2 μg | - | 20 / 40 hrs | 99 | 385 | 16 | 1.83 | 73 | 411 | 16 | 1.89 | 1.86 | 14.1 |
″ | 187.7 μg | - | 20 / 40 hrs | 274 | 222 | 4 | 1.46 | 352 | 144 | 4 | 1.3 | 1.38 | 61.8 |
* c1: mononucleate cells; c2: binucleate cells; c4-c8: multinucleate cells
# DMSO
## Demecolcin
n.c. Not calculated as the CBPI is equal or higher than the solvent control value
Number of micronucleated cells; exposure period 20 hrs without S9 mix
Treatment group | Conc. per mL | S9 mix | Exposure/preparation | Binucleate cells with n micronuclei culture 1 | sum culture 1 | Micronucleated cells Binucleate cells with n micronuclei culture 2 | sum culture 2 | sum in 2000 binucleate cells | [%] | ||||
1 | 2 | >2 | 1 | 2 | >2 | ||||||||
Solv. control# | 0.50% | - | 20 / 40 hrs | 6 | 0 | 0 | 6 | 4 | 1 | 0 | 5 | 11 | 0.55 |
Pos. control## | 125.0 ng | - | 20 / 40 hrs | 22 | 5 | 2 | 29 | 28 | 6 | 0 | 34 | 63 | 3.15 |
Test item | 35.0 μg | - | 20 / 40 hrs | 6 | 0 | 0 | 6 | 4 | 0 | 0 | 4 | 10 | 0.5 |
″ | 61.3 μg | - | 20 / 40 hrs | 10 | 0 | 0 | 10 | 8 | 1 | 0 | 9 | 19 | 0.95 |
″ | 107.2 μg | - | 20 / 40 hrs | 3 | 0 | 0 | 3 | 4 | 0 | 0 | 4 | 7 | 0.35 |
# DMSO
## Demecolcin
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
For the assessment of genetic toxicity there are three key studies (in vitro tests) available: one Ames test, one in vitro micronucleus test and one in vitro gene mutation test in mammalian cells (HPRT). As supporting studies two additional tests are available: one sister chromatid exchange assay and one chromosomal aberration test.
In the first study no OECD guideline was followed, however, the method of Ames, McCann & Yamasaki (1975) is similar to the OECD Guideline 471. S. typhimurium strains TA92, TA1535, TA100, TA1537, TA94 and TA98 were included in the study and the genotoxicity was investigated with and without metabolic activation (S9). The test item was negative in all strains, no significant increase in revertant colonies was detected up to the maximum dose of 5.0 mg/plate.
In the second study the potential of the test item to induce chromosomal aberrations was investigated in an in vitro micronucleus assay according to OECD 487. The induction of cytogenetic damage in human lymphocytes was assessed in two independent experiments.
In each experimental group two parallel cultures were analysed for cytogenetic damage. The highest concentration was 1760.0μg/mL.
In both independent experiments, neither a statistically significant nor a biologically relevant increase in the number of micronucleated cells was observed after treatment with the test item.
Appropriate mutagens were used as positive controls. They induced statistically significant increases in cells with micronuclei.
Therefore, under the experimental conditions reported here, the test item did not induce micronuclei as determined by the in vitro micronucleus test in human lymphocytes and is considered to be not mutagenic (not clastogenic and not aneugenic).
In the third study the potential of the test item to induce gene mutations was assessed in Chinese hamster cells according to OECD 476. The V79 cells were exposed to the test item both with and without exogenous metabolic activation and after treatment the descendants of the treated cells were monitored for the loss of functional HPRT enzyme. The cells were exposed for 4 hours in the first experiment with and without metabolic activation, and in the second experiment for 4 and 24 hours with and without metabolic activation.
The concentration range of the main experiments was limited by cytotoxicity and solubility of the test item.
The tested concentrations were in Experiment I: 6.9; 13.8; 27.5; 55, 110 and 220 µg/mL and in Experiment II: for 24 hours: 13.8; 27.5; 55, 110, 165 and 220 µg/mL; for 4 hours: 6.9; 13.8; 27.5; 55, 110 and 220 µg/mL.
No substantial and reproducible dose dependent increase of the mutation frequency was observed in both main experiments while the positive controls induced a distinct increase in mutant colonies. Under the experimental conditions the test item did not induce gene mutations at the HPRT locus in V79 cells. Therefore, the test item is considered to be non-mutagenic in this HPRT assay.
In the first supporting study the potential of the test item to modify MMC-induced sister-chromatid exchanges (SCEs) was assessed. No OECD guideline was followed, however, the method is comparable to OECD 479. Cultured Chinese hamster CHO K-1 cells were used. No effect on the cell cycle and spontaneous SCEs were observed. However, an increase in SCE frequency occurred by post-treatment with the test substance on MMC-treated cells.
In the second supporting study the potential of the test item to induce chromosome aberrations was assessed in a study similar to the OECD 473. Chinese hamster fibroblast cells were exposed for 24 and 48 hours, without metabolic activation. Chromosome preparations were made and 100 well-spread metaphases were observed under the microscope. The incidence of polyploid cells as well as of cells with structural chromosomal aberrations such as chromatid or chromosome gaps, breaks, exchanges, ring formations, fragmentations and others, were recorded.
The test item was found to be equivocal because even though polyploidisation effects were observed, the percentage was below 10% and no structural aberrations were observed after 48 hours. The maximum dose of the test item was 0.063 mg/mL.
In conclusion, the test item did not induce gene mutations or chromosome aberrations in 5 independent studies. Therefore, the test item is considered to be non-mutagenic.
Justification for classification or non-classification
The test item did not induce gene mutations or chromosome aberrations in 5 independent studies.
According to the criteria set in the Regulation EC No 1272/2008 in section 3.5 the test item is not to be considered as genotoxic/mutagenic.
The available data on genetic toxicity of the test substance do not meet the criteria for classification according to Regulation EC No 1272/2008, and are therefore conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.